Safety Evaluation and Population Pharmacokinetics of Camostat Mesylate and Its Major Metabolites Using a Phase I Study

Camostat mesylate is expected to be promising as a treatment option for COVID-19, in addition to other indications for which it is currently used. Furthermore, in vitro experiments have confirmed the potential of camostat and its metabolites to be effective against COVID-19. Therefore, clinical tria...

Full description

Saved in:
Bibliographic Details
Main Authors: Gwanyoung Kim (Author), Hyun-ki Moon (Author), Taeheon Kim (Author), So-hye Yun (Author), Hwi-yeol Yun (Author), Jang Hee Hong (Author), Dae-Duk Kim (Author)
Format: Book
Published: MDPI AG, 2023-09-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_3c4b1268c7834b388b8fa2752ee80e1c
042 |a dc 
100 1 0 |a Gwanyoung Kim  |e author 
700 1 0 |a Hyun-ki Moon  |e author 
700 1 0 |a Taeheon Kim  |e author 
700 1 0 |a So-hye Yun  |e author 
700 1 0 |a Hwi-yeol Yun  |e author 
700 1 0 |a Jang Hee Hong  |e author 
700 1 0 |a Dae-Duk Kim  |e author 
245 0 0 |a Safety Evaluation and Population Pharmacokinetics of Camostat Mesylate and Its Major Metabolites Using a Phase I Study 
260 |b MDPI AG,   |c 2023-09-01T00:00:00Z. 
500 |a 10.3390/pharmaceutics15092357 
500 |a 1999-4923 
520 |a Camostat mesylate is expected to be promising as a treatment option for COVID-19, in addition to other indications for which it is currently used. Furthermore, in vitro experiments have confirmed the potential of camostat and its metabolites to be effective against COVID-19. Therefore, clinical trials were conducted to evaluate the safety and pharmacokinetic characteristics of camostat after single-dose administration. Additionally, we aim to predict the pharmacokinetics of repeated dosing through modeling and simulation based on clinical trials. Clinical trials were conducted on healthy Korean adults, and an analysis was carried out of the metabolites of camostat, GBPA, and GBA. Pharmacokinetic modeling and simulation were performed using Monolix. There were no safety issues (AEs, physical examinations, clinical laboratory tests, vital sign measurements, and ECG) during the clinical trial. The pharmacokinetic characteristics at various doses were identified. It was confirmed that AUC <sub>last</sub> and C<sub>max</sub> increased in proportion to dose in both GBPA and GBA, and linearity was also confirmed in log-transformed power model regression. Additionally, the accumulation index was predicted (1.12 and 1.08 for GBPA and GBA). The pharmacokinetics of camostat for various dose administrations and indications can be predicted prior to clinical trials using the developed camostat model. Furthermore, it can be used for various indications by connecting it with pharmacodynamic information. 
546 |a EN 
690 |a camostat mesylate 
690 |a GBPA 
690 |a GBA 
690 |a population pharmacokinetics 
690 |a modeling 
690 |a simulation 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceutics, Vol 15, Iss 9, p 2357 (2023) 
787 0 |n https://www.mdpi.com/1999-4923/15/9/2357 
787 0 |n https://doaj.org/toc/1999-4923 
856 4 1 |u https://doaj.org/article/3c4b1268c7834b388b8fa2752ee80e1c  |z Connect to this object online.